Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Francis BerenbaumFrancisco Javier BlancoAli GuermaziKenji MikiTakaharu YamabeLars ViktrupRod JunorWilliam CareyMark T BrownChristine R WestKenneth M VerburgPublished in: Annals of the rheumatic diseases (2020)
NCT02709486.